Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Arisa Mizukawa Yoshida, Naohi Isse, Ryoma Shioji, Kazuharu Sunami
BACKGROUND: Adult nephrotic syndrome is a well-known kidney disease that causes heavy proteinuria, hypoalbuminemia, hypercholesterolemia, edema, and hypertension. The treatment varies according to its underlying cause but often faces medication resistance or adverse drug effects. CASE PRESENTATION: A Japanese woman in her 80s presented with nephrotic syndrome after a 3 year latent period of urinary protein and occult blood. She did not have any secondary causes of nephrotic syndrome...
May 3, 2024: Journal of Medical Case Reports
#2
REVIEW
Chuchu Zeng, Yunjie Jin, Yanzhe Wang, Dingyu Zhu, Zhigang Zhang, Xiaoxia Wang
BACKGROUND: Medullary sponge kidney (MSK)is rare in association with glomerulonephritis. We report a patient with medullary sponge kidney, and the kidney biopsy revealed a diagnosis of IgA nephropathy. CASE PRESENTATION: A 27-year-old female presented with hematuria and proteinuria, and imaging studies indicated the presence of medullary spongy kidney. With appropriate preparation, a kidney biopsy was performed. Considering the patient's clinical and pathological characteristics, the final diagnosis was determined to be medullary sponge kidney associated by IgA nephropathy...
May 3, 2024: BMC Nephrology
#3
JOURNAL ARTICLE
Sanjivani Shrestha, Silvia Malvica, Samir C Gautam, Serena Bagnasco
No abstract text is available yet for this article.
May 3, 2024: Virchows Archiv: An International Journal of Pathology
#4
JOURNAL ARTICLE
Min Yu, Mei Xue, Xiaoyan Fan, Chunlin Gao, Zhengkun Xia
BACKGROUND: Nephrotic syndrome, a prevalent childhood glomerular disorder, manifests with proteinuria, hypoalbuminemia, edema, and hypercholesteremia. Hypercalcemia, though rare, occasionally complicates these cases. Familial hypocalciuric hypercalcemia, an autosomal dominant disorder, is characterized by lifelong hypercalcemia, hypocalciuria, and normal or elevated parathyroid hormone levels due to loss-of-function mutations. CASE PRESENTATION: We detail a 2-year-old girl with nephrotic syndrome whose proteinuria responded effectively to steroid therapy without side effects...
May 3, 2024: Alternative Therapies in Health and Medicine
#5
JOURNAL ARTICLE
Jingwen Feng, Yi Zhao, Lin Zhai, Jingxu Zhou
BACKGROUND AND OBJECTIVE: The application of transarterial chemoembolization (TACE) in combination with targeted therapy and immunotherapy (TACE-T-I) for unresectable hepatocellular carcinoma (HCC) has gained increasing attention. However, there are variations in the efficacy and safety outcomes between TACE-T-I versus TACE combined with targeted drugs (TACE-T). This study aims to systematically evaluate the efficacy and safety of TACE-T-I versus TACE-T in unresectable HCC. METHODS: PubMed, Embase, Cochrane Library, and Web of Science databases were searched from inception to August 21, 2023, for comparative studies on TACE-T-I versus TACE-T for unresectable HCC...
May 3, 2024: Medicine (Baltimore)
#6
JOURNAL ARTICLE
Larabe Farrukh, Virginia Steen, Lee Shapiro, Geovani Faddoul, Swati Mehta
BACKGROUND: Systemic sclerosis (SSc) is a multi-system rheumatic disease characterized by vascular and fibrotic manifestations that can affect practically every organ. Scleroderma renal crisis (SRC) is the most common renal manifestation of SSc. However, with the use of angiotensin-converting enzyme inhibitors (ACEi), the morbidity and mortality associated with SRC has significantly reduced. Renal manifestations in SSc other than SRC have been generally under-recognized and can be left untreated, which can lead to grave consequences in this patient population...
May 3, 2024: Clinical Nephrology
#7
Yuanyuan Jiang, Pei Chen, Wenjing Zhao, Lijun Liu, Sufang Shi, Jicheng Lv, Hong Zhang
[This corrects the article DOI: 10.3389/fmed.2024.1344219.].
2024: Frontiers in Medicine
#8
JOURNAL ARTICLE
Maria Elena Malighetti, Matteo Faletto
Immunoglobulin A (IgA) nephropathy is a common glomerulonephritis, but its treatment remains matter of debate. Recommendation for corticosteroids has been supported, but renin-angiotensin inhibitors, RAAS, and sodium-glucose co-transporter 2 inhibitors (SGLT2i) are increasingly used because of a better benefit/safety balance in comparison with systemic steroids and immunosuppressive treatments. In this case report, a patient with type 2 diabetes (T2DM) and biopsy-proven nephrotic IgA-related nephropathy documented a rapid meaningful reduction of proteinuria and the effect was persistent for 2 years, after receiving the treatment with a GLP1-RA on top of the previous treatment with ACE-inhibitors and SGLT2-i...
April 29, 2024: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
#9
JOURNAL ARTICLE
Yan Yu, Wenqiu Xu, Sufen Zhang, Suihua Feng, Feng Feng, Junshang Dai, Xiao Zhang, Peirun Tian, Shunyao Wang, Zhiguang Zhao, Wenrui Zhao, Liping Guan, Zhixu Qiu, Jianguo Zhang, Huanhuan Peng, Jiawei Lin, Qun Zhang, Weiping Chen, Huahua Li, Qiang Zhao, Gefei Xiao, Zhongzhe Li, Shihao Zhou, Can Peng, Zhen Xu, Jingjing Zhang, Rui Zhang, Xiaohong He, Hua Li, Jia Li, Xiaohong Ruan, Lijian Zhao, Jun He
BACKGROUND: Preeclampsia (PE) is a pregnancy complication defined by new onset hypertension and proteinuria or other maternal organ damage after 20 weeks of gestation. Although non-invasive prenatal testing (NIPT) has been widely used to detect fetal chromosomal abnormalities during pregnancy, its performance in combination with maternal risk factors to screen for PE has not been extensively validated. Our aim was to develop and validate classifiers that predict early- or late-onset PE using the maternal plasma cell-free DNA (cfDNA) profile and clinical risk factors...
2024: Frontiers in Medicine
#10
JOURNAL ARTICLE
Rana A Nabalawi, Mohammed Abdullah Bamuflih, Abdullah Alaa Farid, Khalid Ghali Almramhi, Muhannad Salem Dawood, Mohammad Salah Ahmed, Khaled S Alfawaz, Abdulaziz Mustafa Adnan
BACKGROUND: Chronic kidney disease (CKD) has emerged as a significant global health concern, with its incidence doubling over the past three decades. Cardiovascular diseases (CVD) pose a major threat to CKD patients, surpassing the risk of progressing to end-stage renal disease. While previous studies worldwide have shed light on this association, limited research has been conducted in Saudi Arabia regarding this burden. This study aims to fill this gap by identifying the prevalence and risk factors of CVD in CKD patients at King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia, between 2017 and 2022...
April 2024: Curēus
#11
JOURNAL ARTICLE
Akira Mima, Hidemasa Gotoda, Shinji Lee
Introduction Dotinurad is being developed as a selective uric acid reabsorption inhibitor. However, its effect on lowering serum uric acid (UA) levels in chronic kidney disease (CKD) patients with severe renal dysfunction is unknown. Therefore, the purpose of this study was to determine the effect of dotinurad on renal function in CKD patients with an estimated glomerular filtration rate (eGFR) below 25 mL/min/1.73 m2 . Methods Seven patients with CKD who received dotinurad 0.5 mg to 4 mg per day were studied retrospectively...
March 2024: Curēus
#12
JOURNAL ARTICLE
Atsuki Ide, Keisuke Ota, Miho Murashima, Kodai Suzuki, Takahisa Kasugai, Yuki Miyaguchi, Tatsuya Tomonari, Minamo Ono, Masashi Mizuno, Maki Hiratsuka, Takeshi Kawai, Takashi Suzuki, Kazutaka Murakami, Takayuki Hamano
BACKGROUND: The Kidney Disease Improving Global Outcomes guidelines recommend nephrology referral for patients with chronic kidney disease (CKD) stages 4 to 5, significant proteinuria and persistent microscopic haematuria. However, the recommendations are opinion-based and which patients with CKD benefit more from nephrology referral has not been elucidated. METHODS: In this retrospective cohort study, patients referred to our nephrology outpatient clinic from April 2017 to March 2019 were included...
May 1, 2024: Nephrology
#13
JOURNAL ARTICLE
Florian G Scurt, Verena Hirschfeld, Maximilian J Ganz, Carolin Herzog, Peter R Mertens, Hermann-Josef Gröne, Christos Chatzikyrkou
BACKGROUND: Predicting the outcome of ANCA-associated vasculitis (AAV) is a difficult task. One of the most promising prognostic scores, the ANCA Renal Risk Score (ARRS), has recently been updated and renamed to ANCA Kidney Risk Score (AKRiS). We wanted to test its performance in our population. METHODS: 164 patients were included and categorized in subgroups analogous to that of both scores. Multivariable logistic regression analysis was applied to assess the risk of renal failure...
May 1, 2024: Kidney360
#14
JOURNAL ARTICLE
Yuanjin Song, Lili Sun, Dongning Feng, Qing Sun, Yibing Wang
BACKGROUND: X-linked agammaglobulinemia (XLA) is a primary immunodeficiency disease caused by mutations in the Bruton tyrosine kinase (BTK) gene. Individuals diagnosed with XLA are at an increased risk of developing autoimmune diseases. However, renal involvement are rare in cases of XLA. CASE PRESENTATION: In this report, we discussed a specific case involving a 6-year-old boy with XLA who experienced recurrent upper respiratory tract infections since the age of one...
April 30, 2024: BMC Pediatrics
#15
JOURNAL ARTICLE
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Federico Rossari, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Francesca Bergamo, Elisabeth Amadeo, Francesco Vitiello, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Massimo Alberto Iavarone, Giuseppe Cabibbo, Margarida Montes, Francesco Giuseppe Foschi, Caterina Vivaldi, Caterina Soldà, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Mariangela Bruccoleri, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Hiraoka, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Silvia Foti, Silvia Camera, Fabio Piscaglia, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
BACKGROUND: In the context of patients with hepatocellular carcinoma (HCC) treated with systemic therapy, the correlation between the appearance of adverse events (AEs) and reported efficacy outcomes is well-known and widely investigated. From other pathological settings, we are aware of the prognostic and predictive value of the occurrence of immune-related AEs in patients treated with immune-checkpoint inhibitors. OBJECTIVE: This retrospective multicenter real-world study aims to investigate the potential prognostic value of AEs in patients with HCC treated with atezolizumab plus bevacizumab in the first-line setting...
April 30, 2024: Targeted Oncology
#16
JOURNAL ARTICLE
Anne-Laure Faucon, Sigrid Lundberg, Stefania Lando, Julia Wijkström, Mårten Segelmark, Marie Evans, Juan-Jesús Carrero
BACKGROUND & HYPOTHESIS: KDIGO recommends proteinuria <1 g/d as a treatment target in patients with immunoglobulin A nephropathy (IgAN) because of high-risk of progression to kidney failure. However, long-term kidney outcomes in patients with low-grade proteinuria remain insufficiently studied. METHODS: We enrolled patients with biopsy-proven primary IgAN from the Swedish Renal Registry and analyzed associations between urine albumin-to-creatinine ratio (uACR, in categories < 0...
April 30, 2024: Nephrology, Dialysis, Transplantation
#17
JOURNAL ARTICLE
Kyoichi Kaira, Hiroaki Amano, Hisao Imai, Hirokazu Okada, Hiroshi Kagamu
BACKGROUND/AIM: Membranous nephropathy (MN) is a nephrotic syndrome with both idiopathic and secondary etiologies. The mechanism of cancer-associated MN is presumed to involve the immunological production of antibodies against a tumor antigen, although little is known about the detailed mechanism. Lung cancer is a major neoplasm associated with cancer-associated MN. However, the simultaneous occurrence of secondary MN in patients with cancer of unknown primary (CUP) remains unclear. CASE REPORT: Here, we present a case of secondary MN in a 72-year-old female as a paraneoplastic syndrome in CUP...
2024: In Vivo
#18
JOURNAL ARTICLE
Yajin Chen, Cheng-You Du, Shunli Shen, Wu Zhang, Yunfeng Shan, Ang Lyu, Jianhui Wu, Changzhen Shang, Xuan Luo, Jinxing Wei, Heng Xiao, Jianguo Qiu, Yunpeng Hua, Shutong Wang, Ting Wang, Shengjie Dai, Shuhao Zhang, Bingying Xie, Yinghao Wu, Chunyi Hao
PURPOSE: This phase II, multicenter, prospective, single-arm study aimed to evaluate the efficacy and safety of toripalimab plus bevacizumab in treating advanced hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Treatment-naïve patients with advanced HCC received toripalimab 240 mg plus bevacizumab 15 mg/kg every 3 weeks. Primary endpoints included safety and tolerability, and objective response rate (ORR) assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1...
April 30, 2024: Clinical Cancer Research
#19
JOURNAL ARTICLE
Anne-Kristina Mercier, Abigail K Kois, Deeyen Karsanji, Richard Baldry, Filip Birve, Maria Hedwall, Oleksandr Molodetskyi, Michael Gillen
The endothelin A receptor antagonist zibotentan, combined with the sodium-glucose co-transporter-2 inhibitor dapagliflozin, is being investigated for the treatment of chronic kidney disease with high proteinuria. To allow women of childbearing potential access to this treatment, highly effective contraception is required and drug interactions compromising contraception reliability must be avoided. This study investigated the risk of pharmacokinetic (PK) interaction between zibotentan and the contraceptives ethinyl estradiol and levonorgestrel...
April 30, 2024: Clinical Pharmacology and Therapeutics
#20
JOURNAL ARTICLE
Ping L Zhang, Brandon D Metcalf, Sarang Khan, Jamal Abukhaled, Khalid Zafar, Wei Li, Hassan D Kanaan
CONTEXT: IgM-dominant immune complex-mediated glomerulonephritis (IgM-dominant ICMGN) is a rare renal entity, characterized by a membranoproliferative pattern by light microscopy, dominant IgM staining by immunofluorescent staining, and subendothelial deposits by electron microscopy. This study was to investigate if some of IgM-ICMGN were associated with autoimmune disorders induced by hydralazine. DESIGN: Seven IgM-dominant ICMGN cases were identified over 8 years...
April 29, 2024: Ultrastructural Pathology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
